Chengdu Huide Pharmaceutical Technology

Chengdu Huide Pharmaceutical is a clinical-stage biotechnology company headquartered in Chengdu, China, dedicated to the discovery of innovative small molecule drugs. The company utilizes a proprietary structure-based drug design (SBDD) platform to address challenging targets in metabolic diseases, oncology, and immunology. Its lead candidate, HD-627, is an orally bioavailable GLP-1 receptor agonist currently being evaluated for the treatment of type 2 diabetes and obesity. Huide Pharmaceutical's R&D strategy focuses on improving patient compliance and therapeutic efficacy through oral delivery of traditionally injectable biologics. The leadership team comprises seasoned experts from global pharmaceutical giants, supported by prominent venture capital investors. The company aims to provide high-quality, affordable oral medications for chronic diseases on a global scale.